The oncologist
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.
Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Justyna Żubrowska, Lenka Rušinová, Hana Študentová, Aleksandra Konieczna, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik-Resko
Published: 202610.1093/oncolo/oyag014
Abstract
BACKGROUND: Sacituzumab govitecan (SG), an antibody-drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in heavily pretreated metastatic triple-negative breast cancer (mTNBC) in the ASCENT trial. However, real-w…
Preview only. Read the full abstract at the source